 Representing one of the top performers on Monday, shares of Viridian Therapeutics NASDAQ: VRDN skyrocketed as much as 60. The biotechnology firm released encouraging results for its therapeutic focusing on thyroid eye disease TED, a rare autoimmune disease. 